Vasorelaxant effect of harman.

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Natural Products Chemistry

Background:

• Harmala alkaloids, including harman from Peganum harmala, are known for their diverse biological activities.
• Understanding the cardiovascular effects of harman is crucial for its potential therapeutic applications.

Purpose of the Study:

• To investigate the in vivo cardiovascular effects and in vitro vasorelaxant properties of harman.
• To elucidate the mechanisms underlying harman's hypotensive and vasorelaxant actions.

Main Methods:

• In vivo studies in pentobarbital-anesthetized rats to assess cardiovascular parameters (hypotension, bradycardia).
• In vitro studies using isolated rat thoracic aortic rings to evaluate vasorelaxant effects on phenylephrine-induced contractions.
• Assessment of nitric oxide (NO) release in cultured rat aortic endothelial cells.
• Receptor binding assays to determine interactions with adrenergic, serotonergic, and calcium channels.

Main Results:

• Harman induced dose-dependent hypotension and bradycardia in rats, attenuated by nitric oxide synthase inhibition.
• Harman demonstrated concentration-dependent vasorelaxation in aortic rings, dependent on endothelial nitric oxide (NO) release.
• Harman inhibited contractions induced by various agents in endothelium-denuded aortic rings, suggesting direct smooth muscle effects.
• Receptor binding studies indicated harman interacts with alpha(1)-adrenoceptors, 5-HT(2) receptors, and L-type Ca(2+) channels.

Conclusions:

• Harman's vasorelaxant effect is mediated by endothelial NO release and direct inhibition of vascular smooth muscle contraction.
• Harman's actions on receptor-linked and voltage-dependent calcium channels contribute to its vasorelaxant and potential hypotensive effects.